Stem Cell Action Coalition Opposes Oklahoma House Bill 2070

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Stem Cell Action Coalition Opposes Oklahoma House Bill 2070

WASHINGTON, March 21, 2014 (GLOBE NEWSWIRE) -- The Stem Cell Action Coalition, comprised of medical and scientific societies, patient groups and medical philanthropies from around the world, calls for the Oklahoma Senate to reject the "Protection of Human Life Act of 2013, " which would make embryonic stem cell research a felony.

The Oklahoma House passed the Act (HB 2070) criminalizing embryonic stem cell research and defining "human embryos" as including "single-celled stage, not located in the body of a female."

Bernard Siegel, J.D., spokesperson of the Coalition said, "The Stem Cell Action Coalition joins the Oklahoma State Medical Association in opposing this extreme legislation. Embryonic stem cell research holds the promise of discovering the root causes of disease, serves as a tool for drug discovery, and will surely lead to regenerative medicines and cell therapies for repairing or replacing damaged tissues and organs. A single-cell in a lab dish should not be defined as a 'human embryo.'" Siegel continued. "Oklahoma aspires to become a center for biomedical research and biotechnology, and this legislation sends the worst message."

Should the Act become law, Oklahoma couples who choose to donate their surplus embryos from IVF treatment for humanitarian biomedical research would become felons, subject to severe penalties of prison terms of one year to life imprisonment and a fine of at least $100,000. Clinicians, researchers, their assistants and others involved in biomedical research utilizing the donated embryos would be subject to the same Draconian penalties.

The House further declared the situation an "emergency" and that the Act was necessary for the "preservation of the public peace, health and safety."

Should this bill become law, Oklahoma would interfere with reproductive and related rights of couples along several fronts. These interferences include making it a felony for infertile couples in Oklahoma to donate IVF-created embryos for research. These extra embryos are not needed for implantation or not healthy for implantation and otherwise discarded as medical waste, or frozen in perpetuity. Moreover, the bill would prevent the pursuit of meritorious medical research in Oklahoma that utilizes human embryonic stem cells.

Legislation that limits medical research in one state creates uncertainty for research institutions and biotechnology companies across the U.S. Human embryonic stem cell research has been described by scientists as the "gold standard" for those seeking to develop cures based on stem cell technology for many diseases and maladies such as Parkinson's, ALS, diabetes, MS, macular degeneration and other causes of blindness, spinal cord injuries, and a host of other medical conditions for which there is no known cure. Stem cell research must be supported to accelerate new cures and treatments.

ABOUT STEM CELL ACTION COALITION: An initiative of the Genetics Policy Institute (GPI), the Stem Cell Action Coalition is a grassroots network uniting the Pro-Cures Movement. More than 100 organizations have joined Stem Cell Action Coalition to speak with one voice, building public awareness and coordinating outreach efforts to protect and advance human embryonic stem cell research. The Coalition monitors legislative efforts and litigation impacting the field. Our goal is to secure public support and appreciation for stem cell research. Learn more at www.stemcellaction.org .

Joseph Dawson Communications Manager Stem Cell Action Coalition (561) 578-5975

Scroll down for more posts ▼

Top 10 Most Recent News Articles

SVRN Taps Industry Vet Patrick O'Kain as COO

Updated Category News Views 54

SVRN Aims for New Heights with a Savvy Hire If there’s one thing veteran market-watchers like myself know, it’s that leadership shifts can tell you more about a company’s guts than any press release. SVRN (NASDAQ: SVRN), a name with one foot firmly in the world of digital assets, just snagged Patrick O’Kain for their COO spot. They're not playing around, folks,...

Continue Reading
Survey Reveals 'TDS' Impact on 2026 Midterm Elections

Updated Category News Views 70

Midterms and 'Trump Derangement Syndrome': What's the Deal? Every election season there's something new to raise eyebrows, and this time it's 'Trump Derangement Syndrome' (TDS) taking the spotlight. After the dust of the 2026 mid-terms started settling, it turns out there's more than just traditional candidate bickering shaping votes. Can you guess what's driving voters?...

Continue Reading
Sempra Shines with Robust Q3 2026 Financials

Updated Category News Views 0

Strong Q3 Numbers Set the Scene It’s not every day you see a company cough up numbers that speak volumes. Sempra’s third quarter for 2026 paints a picture of solid performance, boasting earnings of $877 million or $1.34 per diluted share per GAAP standards. That’s an eye-opener compared to the paltry $77 million or $0.12 per share they reported same time last year....

Continue Reading
Coastal Financial Faces Class Action Suit Over Securities

Updated Category News Views 78

Securities Law Tangles: Coastal Financial Hits a Snag There's no dodging it—Coastal Financial Corporation's dogged by a class action lawsuit, and investors need to sit up and take notice. This kind of legal fracas can hit the stock price like a brick through a window, especially when alleged securities law violations crop up. DJS Law Group's got the reins on this one,...

Continue Reading
Grant Davis Joins Assembly Health as CXO

Updated Category News Views 101

Shuffling Pieces in Healthcare Management Change is constant in healthcare management, folks, and it's all about finding the right puzzle pieces. That's what Assembly Health has done by welcoming Grant Davis as their new Chief Experience Officer (CXO). Yeah, you heard me right. It's not a CEO or a CFO, but the CXO role that's under the spotlight this time around, aiming...

Continue Reading
MAURE's Three-Year Mark: Crafting Home Elegance

Updated Category News Views 53

Brooklyn's Gem: MAURE Turns Three Over in Brooklyn, there's a brand bubbling with style called MAURE. Now, we're talking three years strong, surviving the wild bout of the retail scene with a firm two feet planted in home and gifting. The Vision Turned Reality When Maureen Cavalieri, a hospitality veteran since 2009, first tossed this spark into the wind in 2023, it...

Continue Reading
Dizal Unveils Promising Data at ASH 2026

Updated Category News Views 72

Pushing the Horizons in Hematological Research From the bustling streets of Shanghai to the global stage of the ASH 2026, Dizal has made its mark again. This year's presentations could very well shake up the hematological landscape, showcasing new possibilities for treatment strategies. Golidocitinib: A Game-Changer? Now here's a ticket we've been watching with some high...

Continue Reading
LOA Roofing's Growth Recap Taps Southstone's Backing

Updated Category News Views 107

Pardon my skepticism, but when a roofing company names itself Life of Abundance, you know they're aiming to hit it big or at least make you think they're onto something special. LOA Roofing and Construction, holding its ground as a major player in the Central Texas market, set the stage for more ambitious growth. And they found themselves a dance partner in Southstone...

Continue Reading
SKF's Industrial Push: Energy Efficiency at COP31

Updated Category News Views 17

SKF's Green Initiative: A Major Step Forward You ever find yourself in a room full of big players, each trying to outdo the other? That's the stage set for SKF at COP31, where they're not just strutting around showing off but actually offering some substance—a rarity in these highbrow gatherings. They're juicing up the talk around energy efficiency and circularity...

Continue Reading
Eli Lilly's Retatrutide Trials Signal Innovation

Updated Category News Views 48

Unpacking Lilly's Latest Rheumatology Innovations Lilly's taking the stage at ACR Convergence 2026 with a potent arsenal of data that’s got folks buzzing. The company’s put the pedal to the metal on understanding the intertwining chords of obesity and rheumatologic conditions, and boy, are they not messing around. Retatrutide: A Triple Threat in the Making Headlining...

Continue Reading

Top 5 Most Recently Viewed Articles

SKYX Technologies Expands Market Presence with Insider Investments

Updated Category News Views 166

SKYX Technologies' Corporate Developments SKYX Technologies, also known as SKYX (NASDAQ: SKYX), is taking significant strides in the smart technology sector. This dynamic company focuses on transforming homes and buildings into smarter, safer, and more advanced spaces. With a remarkable portfolio of over 97 issued and pending patents, SKYX aims to set a new standard in...

Continue Reading
Crinetics Pharmaceuticals Expands Workforce With Stock Options

Updated Category News Views 195

Crinetics Pharmaceuticals Enhances Employee Incentives In a recent announcement, Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX), based in San Diego, revealed a significant step in enhancing employee incentives and strengthening its workforce. On October 10, 2025, the company’s Compensation Committee authorized the granting of stock options and restricted stock units...

Continue Reading
Manulife Investment Management Earns Top Recognition in Sustainable Finance

Updated Category News Views 199

Manulife Investment Management Recognized for Excellence In a significant acknowledgment of its leadership in sustainable finance, Manulife Investment Management (Manulife IM) has made it to the prestigious list of IPE Real Assets' Top 50 Natural Capital Managers. This recognition comes as the firm is gearing up for robust fundraising activities, with an exciting fund...

Continue Reading
Vaxart Reports Progress and Financial Performance for Q3 2025

Updated Category News Views 213

Vaxart’s Business Progress and Financial Results Overview Vaxart, Inc. (OTCQX: VXRT), a clinical-stage biotechnology company, recently provided a significant update on its business and reported its financial outcomes for the third quarter of 2025. This latest communication showcases exciting developments in their oral recombinant vaccine platform, which is designed to...

Continue Reading
Madrigal Pharmaceuticals Marks Enrollment Milestone in NASH Study

Updated Category News Views 47

Madrigal Pharmaceuticals Achieves Enrollment Milestone in NASH Study Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company dedicated to developing innovative therapies for liver diseases, has announced a significant milestone in their MAESTRO-NASH OUTCOMES clinical trial. This study evaluates the efficacy of resmetirom in patients diagnosed with...

Continue Reading